TREMFYA®: A Giant Leap for Psoriatic Arthritis!

Johnson & Johnson announced groundbreaking new data on the treatment of Psoriatic Arthritis (PsA). TREMFYA® significantly prevents the progression of structural damage at 24 weeks, maintaining this effect up to 48 weeks. These findings were presented at the Inflammatory Skin Disease Summit (ISDS).

In the completed Phase 3b APEX study, more than 50% of patients treated with TREMFYA® achieved a 50% improvement in PsA symptoms by week 48. At week 24, patients treated with TREMFYA® were 2.5 times more effective at preventing structural damage in the joints compared to the placebo group.

Patients in the placebo group who switched to TREMFYA® at week 24 showed a 57% reduction in the rate of joint damage. Dr. Christopher Ritchlin emphasized that PsA is a rapidly progressing disease if left untreated, adding that guselkumab can interrupt this process.

TREMFYA® demonstrated a significant improvement in terms of the American College of Rheumatology's response criteria (ACR50). Both the 4-week and 8-week dosing groups showed an increase in ACR50 response rates. These data are consistent with the well-known safety profile of TREMFYA®.

Leonard Dragone stated that TREMFYA® is the only IL-23 inhibitor capable of preventing structural damage in active PsA. This treatment option offers an attractive first-line therapy opportunity for patients with psoriatic diseases.

TREMFYA® is a fully human monoclonal antibody that neutralizes inflammation at the cellular source by blocking IL-23 and binding to CD64, which is found on the surface of IL-23 producing cells. Johnson & Johnson has also submitted an additional Biologics License Application to the FDA to provide new data on the prevention of structural damage in active PsA patients.